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Abstract The development of smart nanoparticles that can
exhibit the anti-cancer activity, introduces better efficacy
and lower toxicity for treatment. The present study was
aimed to evaluate the anti-cancer activity of surface
functionalized CoO nanoparticles against Jurkat (T-cell
lymphoma) and KB (oral carcinoma) cell lines. The nano-
sized cobalt oxide nanoparticles (CoO) was prepared by
thermal decomposition method followed by surface
modification using phosphonomethyl iminodiacetic acid
(PMIDA). The PMIDA-coated CoO nanoparticle was
characterized by X-ray diffraction, dynamic light scattering,
and transmission electron microscopy; and the conjugation
was analyzed by Fourier transform infrared spectroscopy.
The resultant nanoparticles with an average size less
than 100 nm measured by dynamic light scattering and
transmission electron microscopy. Cytotoxicity study, flow
cytometric analysis and scanning electron micrographs have
been revealed that PMIDA-coated nanoparticles significant-
ly enhances the cellular uptake of the nanoparticle and thus
facilitates apoptosis of cancer cell (Jurkat and KB). For the
application of PMIDA-coated CoO nanoparticles in the
medical field, doxorubicin, a potent anti-cancer drug, has
been used in similar fashion in this experimental design and
all these effects or patterns were observed.
Keywords Cobalt oxide nanoparticles . Cancer cell
line . Anti-cancer drug . Cytotoxicity . Cellular
apoptosis . SEMmicrographs
1 Introduction
The rapid developments of various modified nanoparticles
(NP) are attracting increased attention because of their po-
tential in a wide range of biotechnological applications,
especially in advance biomedical application (Liong et al.
2008), drug delivery systems (Cheng et al. 2006), and
vaccine administration (Schreiber et al. 2010). One of the
most interesting chemical elements used as nanoparticles for
biomedical applications is cobalt (Co) which is mainly used
as cobalt oxide and has an organo-metal compound or a
biopolymer (Wang et al. 2005). In spite of its physiological
role as a co-factor of vitamin B12, cobalt cannot be regarded
only as an essential element. Cobalt-based NPs, in general,
cobalt oxide nanoparticles, in particular, are currently
attracting enormous interest owing to their unique size-
and shape-dependent properties and potential applications
in pigments, catalysis, sensors, electrochemistry, magne-
tism, energy storage, etc. (Liu et al. 2005).
The uses of polymeric nanoparticles with functional
properties have been widely used in a broad range of bio
applications; like drug and gene delivery, cell and tissue
engineering, diagnostic and therapeutic purposes etc.
(Uhrich et al. 1999; Panyam and Labhasetwar 2003; Marin
et al. 2005; Marinakos et al. 2001). Among these applica-
tions, the field of drug delivery by nanoparticles with
S. Chattopadhyay : S. P. Chakraborty : S. Roy (*)
Immunology and Microbiology Laboratory, Department of Human
Physiology with Community Health, Vidyasagar University,
Midnapore 721 102 West Bengal, India
e-mail: roysomenath@hotmail.com
D. Laha : P. Pramanik
Nano materials Laboratory, Department of Chemistry,
Indian Institute of Technology,
Kharagpur, West Bengal, India
R. Baral
Immunoregulation and Immunodiagnostics,
Chittaranjan National Cancer Institute,
Kolkata 700 026, India
Cancer Nano (2012) 3:13–23
DOI 10.1007/s12645-012-0026-z
specific and rapid internalization into a target cell has im-
mense promise (Maeda et al. 2009; Faraji and Wipf 2009;
Singh and Lillard 2009; Breunig et al. 2008; Brannon-
Peppas and Blanchester 2004). Nanoparticles of polymer
not only protect the bioactive substance but also facilitate
the control release of the material in delivering system
(Vauthier et al. 2003; Liang et al. 2006; Sheikh et al.
2009; Mitra et al. 2001). Therefore, in the present paper,
we have focused our interest on the study of modified CoO
NPs. Believing that the characterization of the physical–
chemical properties of NP is relevant for the study of their
biological activity, we analyzed CoO NP morphology by
electron microscopy in order to define aggregation, size, and
shape. These properties may have a significant influence on
their biological effects. This present study was aimed to
develop a novel and economically viable nanoparticles
which have anti-cancer activity to cancer cell in vitro.
2 Materials and methods
2.1 Chemicals and reagents
Phosphonomethyl iminodiacetic acid (PMIDA), propi-
dium iodide, cobalt chloride (CoCl2·3H2O), RNaseA,
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT reagent), Histopaque 1077, and Rhoda-
mine isothiocyanate (RITC) were procured from Sigma
(St. Louis, MO, USA). Minimum essential medium
(MEM), RPMI 1640, fetal bovine serum (FBS), penicil-
lin, streptomycin, doxorubicin, sodium chloride (Nacl),
sodium carbonate (Na2CO3), sucrose, Hanks balanced
salt solution, and ethylene diamine tetra acetate were
purchased from Himedia, India. Tris–HCl, Tris buffer,
KH2PO4, K2HPO4, Hcl, formaldehyde, alcohol, and oth-
er chemicals were procured from Merck Ltd., SRL Pvt.
Ltd., Mumbai, India. Commercially available dimethyl
sulfoxide was procured from Himedia, India, and was
purified by vacuum distillation over KOH. All other chem-
icals were from Merck Ltd., SRL Pvt., Ltd., Mumbai, and
were of the highest purity grade available.
2.2 Synthesis of cobalt oxide nanoparticles
Cobalt oxide NPs were prepared by thermal decomposition
method. The starting materials were CoCl2·3H2O, Na2CO3.
Two grams of starting material (CoCl2·3H2O) was taken in a
beaker and mixed with Na2CO3 as a molar ratio 1:1. Then
the solution was rotated 1 h at room temperature. After that
the precipitations were collected by centrifugation to obtain
the nanoparticle precursor. The precursor was calcinated at
300 °C in air in a porcelain crucible for 2 h to get cobalt
oxide NPs.
2.3 Surface modification of synthesized cobalt oxide
nanoparticles
Thirty milligrams of synthesized cobalt oxide NPs was dis-
persed in 10 ml of milli-Q (Millipore) to make a solution
3 mg/ml. Another solution of PMIDA was prepared by dis-
solving 27 mg PMIDA in 10 ml of distilled water. Then this
solution was mixed with above solution. The pH of the
medium was maintained at 10 and stirring for 12 h. After that
particles were collected by centrifugation. Then the recovered
particles were washed three times with milli-Q (Millipore).
2.4 Characterization of synthesized surface modified cobalt
nanoparticles
2.4.1 X-ray diffraction study
The phase formation and crystallographic state of cobalt oxide
NPs were determined by XRDwith an Expert Pro (Phillips) X-
ray diffractometer using CoKα radiation (¥00.178 nm). Sam-
ples were scanned from 20° to 80° of 2θ increment of 0.04°
with 2 s counting time. Hydrodynamic size of the cobalt oxide
nanoparticles aggregates was measured in a Brookhaven 90
Plus particle size analyzer (Chakraborty et al. 2010).
2.4.2 Dynamic light scattering
Dynamic light scattering (DLS) analysis was done by Zeta-
sizer Nano ZS (Malvern Instruments) according to the method
of Chakraborty et al. (2010) with some modifications. The
concentration of the cobalt oxide nanoparticles was 100 μg/ml
and was sonicated for 2 min and dynamic particle sizes were
measured suspending two drops of aqueous suspension of
nanoparticles in 10 ml of Millipore water. When particle was
completely dispersed in water then particle was analyzed with
a dynamic light scattering analyzer. The experiments were
repeated several times to get average size of nanoparticles.
2.4.3 Transmission electron micrography
The particle size and microstructure were studied by high-
resolution transmission electron microscopy in a JEOL 3010,
Japan operating at 200 kV according to the method of
Chakraborty et al. (2010) with some modifications. In brief,
cobalt oxide nanoparticles was suspended in deionized at a
concentration of 1 mg/ml then the sample was sonicate using a
sonicator bath until sample form a homogenous suspension.
For size measurement, sonicated stock solution of all cobalt
oxide nanoparticles (0.5 mg/ml) was diluted 20 times. TEM
was used to characterize the size and shape of the cobalt oxide
nanoparticles. A drop of aqueous cobalt oxide nanoparticles
suspension was placed on to carbon-coated copper grid and
this was dried in air to get TEM image.
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2.4.4 Fourier transform infrared spectroscopy
The conjugation of PMIDA with CoO nanoparticles was
investigated by the FTIR with a model Thermo Nicolet
Nexux-model 870 according to the method of Chakraborty
et al. (2010) with some modifications. In brief, 1.0 mg
sticky mass of PMIDA-coated CoO nanoparticles with
100 μl KBr medium and a thin film was prepared on the
Nacl plate by drop casting method and under atmosphere
separately. The FTIR value was taken within 500 to 4,000
wave numbers (cm−1).
2.5 Selection of human subjects for collection
of lymphocytes and oral squamous epithelial cell
Six healthy subjects were chosen to collect the blood
sample for separation of lymphocytes and collection of
squamous epithelial cell by scraping. All subjects en-
rolled in this study were asymptomatic and none of
them had abnormality on physical examinations and
routine laboratory tests. All the subjects were from same
geographical area and same economic status, non-
smokers and non-alcoholic, and having same food habit.
These subjects received no medication, including vita-
min E and vitamin C. All subjects gave informed con-
sent. The selection excluded not only individuals with
acute infections or chronic diseases, but also excluded
healthy individuals undergoing supplementation with
antioxidative substances. The study protocol was in accor-
dance with the declaration of Helsinki, and was approved by
the ethical committee of Vidyasagar University.
2.5.1 Separation of lymphocytes
Fasting blood samples were collected from all groups of
individuals satisfying the Helsinki protocol. The lympho-
cytes were isolated from heparinized blood samples
according to the method of Hudson and Hay (Hudson
et al. 1991). Blood was taken and diluted with
phosphate-buffered saline (pH 7.0) in equal ratio and
then layered very carefully on the density gradient (his-
topaque) in 1:2 ratio, centrifuged at 500×g for 40 min
and the white milky layer of mononuclear cells, i.e.,
lymphocytes were carefully removed. The layer was
washed twice with the same buffer and then centrifuged at
2400 rpm for 10 min to get the required pellet of lymphocytes.
2.5.2 Collection of oral squamous epithelial cells
Mucosal scrapings were placed in medium MEM supple-
mented with 10 % fetal bovine serum and then passed
through a sterile 100-mm nylon mesh followed by further
washes with MEM complete medium. Filtrate was
then centrifuged at 2,200–2,400 rpm for 5 min and the
supernatant discarded. The cell pellet is suspended in
MEM supplemented with 10 % fetal bovine serum,
100 μg/ml streptomycin, and 100 U/ml penicillin (Steele
and Fidel 2002).
2.6 Cell culture
The normal human lymphocytes and oral squamous epithe-
lial cells, T-cell lymphoma (Jurkat) and oral epithelial cancer
(KB) cell lines were cultivated for in vitro experiments. Cell
lines were obtained from the National Centre for Cell
Sciences, Pune, India. It was cultured in RPMI 1640 medi-
um and minimal essential medium supplemented with 10 %
fetal calf serum, 100 U/ml penicillin, and 100 μg/ml strep-
tomycin, 4 mM L-glutamine under 5 % CO2, and 95 %
humidified atmosphere at 37 °C.
Fig. 1 X-ray diffraction analysis of cobalt oxide nanoparticles

















Fig. 2 The size determination of cobalt oxide nanoparticles by dynamic
light scattering
In vitro anti-cancer activity of surface-modified CoO nanoparticles 15
2.7 Preparation of drug
Several doses of PMIDA-coated CoO nanoparticles and
doxorubicin (1–25 μg/ml) were prepared using sterile phos-
phate buffer saline (pH 7.4). In this study, all these doses
were charged against normal and cancer cell line for evalu-
ation of in vitro anti-cancer activity.
2.8 Experimental design
Each type of cells was divided into nine groups. Each group
contained six Petri dishes (2×105 cells in each). The cells of
each Petri dishes of control and experimental groups were
maintained in MEM and RPMI 1640 media, where as it is
applicable, supplemented with 10 % FBS, 50 μg/ml genta-
mycin, 50 μg/ml penicillin, and 50 μg/ml streptomycin at
37 °C in a 95 % air/5 % CO2 atmosphere in CO2 incubator.
The following groups were considered for the experiment
and cultured for 48 h:
Group I Control, i.e., cells in culture media
Group II Cells+1 μg/ml doxorubicin in culture media
Group III Cells+1 μg/ml PMIDA-coated CoO nanoparticles
in culture media
Group IV Cells+5 μg/ml doxorubicin in culture media
Group V Cells+5 μg/ml PMIDA-coated CoO nanoparticles
in culture media
Group VI Cells+10 μg/ml doxorubicin in culture media
Group VII Cells+10 μg/ml PMIDA-coated CoO nanopar-
ticles in culture media
Group VIII Cells+25 μg/ml doxorubicin in culture media
Group IX Cells+25 μg/ml PMIDA-coated CoO nanopar-
ticles in culture media
After the treatment schedule, the cells were collected from
the Petri dishes separately and centrifuged at 2,200 rpm for
10 min at 4 °C. The cells were washed twice with 50 mM
PBS, pH 7.4 and then processed for the biochemical estima-
tion (Sandhu and Kaur 2002).
2.9 In vitro cytotoxicity
Normal human lymphocytes and oral squamous epithelial cell,
Jurkat and KB cell lines were seeded into 96 wells of tissue
culture plates having 180 μl of complete media and were
incubated for 48 h. Doxorubicin and PMIDA-coated CoO
nanoparticles were added to the cells at different concentrations
(1, 5, 10, and 25 μg/ml), were incubated for 48 h at 37 °C in a
humidified incubator (NBS) maintained with 5 % CO2. The
Fig. 3 TEM images of PMIDA-coated cobalt oxide nanoparticles



























Fig. 4 FTIR spectra of a
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cell viability was estimated by 3-(4,5-dimethylthiazol)-2-
diphenyltetrazolium bromide according to the method of our
previous laboratory report Chakraborty et al. 2011.
2.10 Detection of cellular apoptosis by flow cytometric
analysis using propidium iodide
Cell apoptosis was measured using propidium iodide stain-
ing and analysis by flow cytometry (Roa et al. 2009). After
the treatment schedule; the cells were scraped and centri-
fuged with the supernatant medium at 3,500 rpm for 5 min.
Following washes, cells were resuspended in PBS and fixed
in 70 % ethanol for 1 h on ice. Fixed cells were washed with
PBS and stained with propidium iodide (5 μg/mL) solution
containing ribonuclease (RNase; 50 μmol/L) for 30 min at
room temperature. Then, cells were analyzed on a Becton
Dickinson FACS Calibur flow cytometer. The sub-G0 pop-
ulation of the cells was determined by CellQuest software.
2.11 Alteration of cellular morphology by scanning electron
microscope
After the treatment schedule, Jurkat and KB cells were exam-
ined under electron microscope according to the method of
Papis et al. (2009) to visualize whether the cell undergoes for
morphological alteration or not. In brief, treated cells were


































































 Control  1 µg/ml  5 µg/ml
 10 µg/ml  25 µg/mlb
Fig. 5 Cytotoxicity of
PMIDA-coated cobalt oxide
nanoparticles against normal
human lymphocytes and squa-
mous epithelial cell (a) and
human T-cell lymphoma and
oral squamous carcinoma cell
lines (b). n06; values are
expressed as mean±SEM.
Asterisks indicate the signifi-
cant difference as compared
to control group
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harvested, fixed in 2 % glutaraldehyde in 0.1M Na-cacodylate
buffer (pH 7.2) for 1 h at room temperature, washed in the
same buffer, and post fixed for 1 h with 1 % osmium tetroxide
in 0.1 M Na-cacodylate buffer (pH 7.2) at room temperature
and dehydrated in graded ethanol and observed under electron
microscope.
2.12 Intracellular uptake
Nanoparticle uptake by Jurkat and KB cells was studied by
fluorescence microscopy methods according to our previous
laboratory report (Sahu et al. 2010). After the treatment schedule,
2×105 cells were seeded into 35 mm cell culture plates. It was
incubated in a humidified incubator maintained with 5 % CO2
and 37 °C. After 8 h the cells were washed with incomplete
media and were incubated with 25 μg/ml DOX/DOX-RITC
and PMIDA-coated CoO NP/PMIDA-coated CoO NP-RITC
for fluorescence microscopy. Then the cells were allowed to
adhere to a glass cover slip in 35-mm Petriplates, followed by
incubation for 4 h at 37 °C in a humidified incubator main-
tained with 5%CO2. Fluorescence images were acquiredwith
488 nm laser for differential interference contrast microscopy
and 543 nm lasers for RITC excitation on an Olympus re-
search phase contrast with fluorescence microscope (model:
CX41; Olympus Singapore Pvt. Ltd., Valley Point Office
Tower, Singapore).
2.13 Statistical analysis
The data were expressed as mean±SEM, n06. Comparisons
between the means of control and treated group were made by
one-way ANOVA test (using a statistical package, Origin 6.1,
Northampton, MA 01060 USA) with multiple comparison




Fig. 6 PMIDA-coated cobalt
oxide nanoparticles induced
cellular apoptosis analysis
in Jurkat cell lines by
flow cytometry using
propidium iodide. Here
a −ve control, b +ve control,
c Jurkat+10 μg/ml PMIDA-
coated CoO nanoparticles,
d Jurkat+10 μg/ml doxorubicin,
e Jurkat+25 μg/ml PMIDA-
coated CoO nanoparticles,
f Jurkat+25 μg/ml doxorubicin
18 S. Chattopadhyay et al.
3 Result and discussion
3.1 Synthesis of PMIDA-coated CoO nanoparticles
Several data are available about the toxicology of cobalt
ions, it is generally accepted that the biological activity and
potential toxicity of metallic NPs cannot simply be derived
from previous data on ionic forms, indicating the impor-
tance of testing the effects of chemicals in nanostructural
form (Roco 2005). The nano-sized cobalt oxide nanopar-
ticles (CoO) was prepared by thermal decomposition method
followed by surface modification using phosphonomethyl
iminodiacetic acid. The phosphonate group of the N phospho-
nomethyl iminodiacetic acid ligand acts as a surface anchoring
agent on nanoparticles and the –COOH remains free at
outside.
3.2 Characterization of synthesized surface modified cobalt
nanoparticle
3.2.1 X-ray diffraction analysis
The XRD pattern of cobalt oxide nanoparticle were compared
and interpreted with standard data of JCPDS file (JCPDS
international center for diffraction data, 1991). The XRD
pattern of cobalt oxide nanoparticles was represented in
Fig. 1. The characteristic peaks at 2θ022.08°, 36.49°, 43.20°,




Fig. 7 PMIDA-coated cobalt
oxide nanoparticles induced
cellular apoptosis analysis in
KB cell lines by flow cytometry
using propidium iodide. Here
a −ve control, b +ve control,
c KB+10 μg/ml PMIDA-
coated CoO nanoparticles,
d KB+10 μg/ml doxorubicin,
e KB+25 μg/ml PMIDA-
coated CoO nanoparticles,
f KB+25 μg/ml doxorubicin
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which are marked respectively by their indices (111), (220),
(311), (400), (511), and (440) agreement with JCPDS card no
73-1701. The X-ray pattern confirmed the phase formation of
cobalt oxide nanoparticle.
3.2.2 Dynamic light scattering experiment
The size distribution of cobalt oxide nanoparticles in aque-
ous medium was characterized by DLS. The mean size of
nanoparticles in aqueous solution was determined to be 70±
12 nm shown in Fig. 2. This study of the particle was further
confirmed by the presence of stable, non aggregate of cobalt
oxide nanoparticle.
3.2.3 Transmission electron microscopy
The TEM morphology of cobalt oxide nanoparticles shows
having nearly spherical geometry with a mean size of less
than 100 nm. The result was represented in Fig. 3. The
presence of some bigger particle should be attributed to be
aggregating or overlapping of some small particle. The
observed nanoparticles size was approximately larger than
the hydrodynamic diameter obtained from the DLS experi-
ment. In TEM described the size in the dried state of the
sample, whereas DLS measured the size in the hydrated
state of the sample, so that the size measured by DLS was
a hydrodynamic diameter and had a larger. However, one
has to bear in mind that by TEM we image single particles,
while DLS gives an average size estimation, which is biased
toward the larger-size end of the population distribution.
3.2.4 Fourier transform infrared spectroscopy
Conjugation of PMIDAwith CoO nanoparticles was investi-
gated by FTIR spectroscopy. The comparison of FTIR spec-
trum of pure CoO nanoparticles, PMIDA, and PMIDA-coated
ca b
d fe
Fig. 8 Scanning electron microscopy shows the intracellular uptake of
PMIDA-coated cobalt oxide nanoparticles into Jurkat and KB cell
lines. a Jurkat control, b Jurkat+25 μg/ml doxorubicin, c Jurkat+
25 μg/ml PMIDA-coated CoO nanoparticles, d KB control, e KB+
25 μg/ml doxorubicin, f KB+25 μg/ml PMIDA-coated CoO
nanoparticles
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CoO are shown in Fig. 4. FTIR spectra shows basic character-
istics IR band of CoO at 570 cm−1, which indicate presence of
CoO vibration and a broad band around 3,440 cm−1 indicative
the presence of –OH groups on the nanoparticle surface. After
conjugation of PMIDA on nanoparticle surface a significant
decrease in the intensity of the band at 3,440 cm−1 which
indicates the conjugation of phosphonic acid on CoO NPs. A
significant band also show at 1,050 cm−1, 1,750 cm−1 for M–
O–P and P 0O respectively which also confirm the successful
conjugation of PMIDA on nanoparticle surface.
3.3 In vitro toxicity studies
The toxicity of the PMIDA-coated CoO nanoparticles was
checked towards normal human lymphocytes and oral squa-
mous epithelial cell in vitro. PMIDA-coated CoO nanopar-
ticles mediated cytotoxicity to these normal cells was
measured by MTT assay (Fig. 5). It was found that there
was no significant difference in cell viability between the
cells treated with PMIDA-coated CoO nanoparticles and the
cell treated without PMIDA-coated CoO nanoparticles. It
was represented in Fig. 5a. Hence these nanoparticles are
expected to be safe for biomedical application. On the other
hand, surprisingly PMIDA-coated CoO nanoparticles exhibits
anti-cancer activity against Jurkat and KB cell lines in a dose-
dependent fashion. It was observed from our experiment,
doxorubicin kills the Jurkat cell and KB cell by 15.64 %,
25.28 %, 40.52 % and 17.08 %, 30.80 %, 42.73 %, respec-
tively, at a dose of 1, 5, and 10 μg/ml; whereas PMIDA-coated
CoO nanoparticles kills the Jurkat and KB cells by 14.2 %,
21.80 %, 34.28 % and 12.20 %, 23.58 %, 35.78 %, respec-
tively. All these changes were insignificant at the level of
p<0.05 (Fig. 5b). But 25 μg/ml doxorubicin and PMIDA-
coated CoO nanoparticles kills the Jurkat and KB cells signif-
icantly (p<0.05) by 61.85 %, 59.76 % and 58.71 %, 59.71 %,
respectively (Fig. 5b). So, it was observed from our results
that PMIDA-coated CoO nanoparticles has little bit least
effect on Jurkat and KB cell lines than doxorubicin
treatment. But our previous experimental data (Fig. 5a)
showed that PMIDA-coated CoO nanoparticles have no
toxic effect on normal human lymphocytes and oral squamous
epithelial cells. Previous research by Karim and his colleagues
in 2001 and Dhawan and his colleagues in 2003 reported that
doxorubicin has toxic effect on normal cells. In this point of
view, PMIDA-coated CoO nanoparticles may have a great
promise in the treatment of cancer because of its no lethal
toxicity on normal cells.
3.4 Cellular apoptosis analysis by flow cytometry
using propidium iodide
To investigate whether PMIDA-coated CoO nanoparticles is
associated with the induction of cellular apoptosis, after the
treatment schedule Jurkat and KB cells were analyzed
fluorescence-activated cell sorter with propidium iodide.
PMIDA-coated CoO nanoparticles induced the cellular ap-
optosis in Jurkat cell lines by 63.25 % and 65.93 %; where
as 37.39 % and 38.77 % in KB cell line. In contrast,
doxorubicin shows 77.53 % and 78.05 % cellular apoptosis
in Jurkat cell lines; whereas and 37.20 % and 46.64 % in KB
cell lines of 10 and 25 μg/ml of PMIDA-coated CoO nano-
particles (Figs. 6 and 7). The cell cycle pattern of those two
cancer cell line shows that the cellular apoptosis proceed
because the nanoparticles has the ability to alter the intra-
cellular antioxidant regulation and plasma membrane struc-






nanoparticles into Jurkat (a)
and KB (b) cell lines
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3.5 Intracellular uptake by scanning electron microscopy
and fluorescence imaging
Nanoparticles binding to the plasma membrane and cellular
uptake are probably a necessary condition for its exertion of
cytotoxicity. We have shown that PMIDA-coated CoO nano-
particles were taken up by Jurkat and KB cell lines in in vitro
cultures and the alteration of cellular structure was observed
(Fig. 8). From the fluorescence images (Fig. 9) the PMIDA-
coated CoO nanoparticles were found to be distributed in the
cytoplasm leaving clear zone of nucleus, indicating cellular
uptake instead of adhesion to the surface and the nanoparticles
preferentially targeted the cancer cells andwere internalized. This
internalizationmight be due to the receptor-mediated endocytosis
(Peters et al. 2007; Gojova et al. 2007; Mohapatra et al. 2007).
4 Conclusion
In this study, a simple process has been developed to syn-
thesize PMIDA-coated CoO nanoparticles. This nano poly-
meric system impact excellent stability in aqueous medium
with reasonable good hydrodynamic size. In vitro cytotox-
icity test using an MTT assay method showed that this
PMIDA-coated CoO nanoparticles has anti-cancer activity;
rather than they have no adverse effect on normal cells.
Flow cytometry has revealed that nanoparticles are targeting
more effectively the cancerous cells. Due to high specific
uptake, this system may further be explored for the applica-
tion of new anti-cancer drug development therapy. The data
presented here suggests that further in vivo studies are
needed to define the therapeutic index of the tumor-
targeting polymeric carrier and will constitute the basis for
the next generation drug development. In vivo testing of
anti-cancer activity of these nanoparticles is in progress.
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